Recent news on Kepivance

Amgen Names David Lacey, MD, Senior Vice President, Head of Research  -  May 23, 2007
PharmaLive.com (press release),The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies. Lacey also played a key role in the discovery

Amgen mulls new uses for plant  -  May 7, 2007
Providence Journal (subscription),The plant now produces Denosumab, an experimental drug for treating bone loss; Kepivance, a medicine for oral mucositis; and AMG 53, an experimental

Kepivance® May Decrease Oral Mucositis Following High-dose ...  -  Jan 10, 2007
Cancer Consultants (press release),Several studies presented at the 2006 meeting of the American society of Hematology in December suggest that Kepivance® (palifermin) decreases the frequency

Kepivance® May Decrease Oral Mucositis Following High-Dose ...  -  Jan 8, 2007
Cancer Consultants (press release),There were several clinical studies presented at the 2006 meeting of the American Society of Hematology in December which suggest that Kepivance

Kepivance® Decreases Oral Mucositis in Patients with Metastatic ...  -  Nov 27, 2006
Cancer Consultants (press release),The results of a randomized multicenter trial demonstate that Kepivance (palifermin, keritinocyte growth factory) given before chemotherapy reduces the ...

The Effects Of Palifermin In Patients With Impaired Kidney ...  -  Dec 14, 2006
Medical News Today (press release),Palifermin (Kepivance) is approved for use to decrease the chances of developing severe mucositis or injury to the cells lining the mouth, as well as shorten ...

Kepivance® Reduces Mucositis After Allogeneic Stem Cell ...  09 Nov 2006
Researchers from the University of Minnesota and Michigan have reported that the administration of Kepivance (palifermin, keritinocyte growth factor) before ... -Cancer Consultants (press release), Kepivance® Reduces Mucositis in Colorectal Cancer Patients ...  09 Nov 2006
According to an early online publication in the Journal of Clinical Oncology, Kepivance® (palifermin) can significantly reduce oral mucositis among patients ... -Cancer Consultants (press release), Kepivance® Reduces Mucositis After Allogeneic Stem Cell ...  Nov 2, 2006
According to an article recently published in the journal Blood, Kepivance® (palifermin, keritinocyte growth factor), given before and after allogeneic stem ... -Cancer Consultants (press release), MGI Drug Approval Falters  Oct 16, 2006
...previously been planning to run a second phase 3 trial but chose not to, most likely as a reaction to the FDA's approval of a similar drug, Kepivance, for oral ... -MSNBC Daily Low Power Laser Therapy May Prevent Oral Mucositis in Stem ...  Oct 25, 2006
At the present time, the main FDA approved treatment for prevention of oral mucositis after autologous stem cell transplantation is Kepivance® (palifermin). ... -Cancer Consultants (press release), Pennsylvania Company Buys RxKinetix  Oct 12, 2006
Amgen Inc., the world's largest biotech company, received FDA approval two years ago for a mucositis treatment, Kepivance, which it produces in Boulder. ... -International News Service, Kepivance® Decreases Oral Mucositis in Patients with Metastatic ...  -  Nov 27, 2006
Cancer Consultants (press release),The results of a randomized multicenter trial demonstate that Kepivance (palifermin, keritinocyte growth factory) given before chemotherapy reduces the

Study in the Journal of Clinical Pharmacology  -  Dec 7, 2006
EurekAlert (press release),Palifermin (Kepivance) is approved for use to decrease the chances of developing severe mucositis or injury to the cells lining the mouth,

L-Glutamine Effective for Prevention of Oral Musositis After ...  Aug 7, 2006
...including local cryotherapy, the administration of Ethyol (amifostine), and the administration of growth factors including Kepivance® (ketatinocyte growth ... -Cancer Consultants

Amgen Moving Jobs to Longmont  Jun 26, 2006
Another 350 Amgen employees work out of offices in east Boulder, making the company's mouth-sore drug Kepivance and other products. ... -International News Service

Amgen confirms hundreds to move  Jun 27, 2006
About 650 people work there today. An additional 350 employees work out of offices in east Boulder, making the mouth-sore drug Kepivance and other products. ... -Ventura County Star (subscription)



Kepivance™ Improves Patient-Assessed Oral Mucositis Following ...  Apr 21, 2006
The results of patient evaluations of a phase III randomized trial of Kepivance™ (palifermin, epidermal growth factor) for the prevention of oral mucositis ... - Cancer Consultants

ConjuChem Announces New Executive Vice President, Research and ...  May 11, 2006
Dr. Ulich served in a pivotal leadership role for the regulatory filings of such highly successful drugs as Aranesp, Neulasta, Kepivance, Sensipar, and ... - Canada NewsWire



Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased ...  Jan 26, 2006
Kepivance (palifermin): The Company announced that Kepivance received regulatory approval in the European Union to decrease the incidence, duration and ... - Biotech Intelligence

Lilly's Gemzar For Ovarian Cancer To Receive Oncologics Cmte. ...  Jan 19, 2006
...of its Pediatric Oncology Subcommittee, which discussed pediatric study commitments for Genzyme’s Clolar, Amgen’s Neulasta and Kepivance, and pediatric ... - FDA Advisory Committee

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional